CG
AVIR icon

Cutler Group’s Atea Pharmaceuticals AVIR Stock Holding History

Cutler Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-31,700
Closed -$12K – 5296
2021
Q4 		$12K Buy
31,700
+29,200
+1,168% +$455K ﹤0.01% 3518
2021
Q3 		$9K Buy
+2,500
New +$69.3K ﹤0.01% 3984

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cutler Group's AVIR Position: Q4 2023 in Review

Cutler Group sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 2,400 shares — an estimated $7K sold.

Cutler Group first reported a position in AVIR in Q2 2021 and held it in 10 quarters. The position peaked at $152K in Q3 2021. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • Cutler Group reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 2,400 Atea Pharmaceuticals shares in Q4 2023, an estimated $7K.
  • Cutler Group first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Cutler Group's Atea Pharmaceuticals position peaked at $152K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.